Mechanisms in endocrinology metabolic and inflammatory pathways on the pathogenesis of type 2 diabetes

European Journal of Endocrinology

Volumn 174, Issue 5, 2016, Pages R175-R187

  Coope, Andressa ^a   Torsoni, Adriana S ^a   Velloso, Licio A ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLICATION; DIABETES MELLITUS, TYPE 2; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; OBESITY;

DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; OBESITY;

EID: 84969921764     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-1065     Document Type: Review

References (163)

1. Muoio DM & Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and b-cell failure in type 2 diabetes. Nature Reviews. Molecular Cell Biology 2008 9 193-205. (doi:10.1038/nrm2327).
2. Kahn SE, Hull RL & Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006 444 840-846. (doi:10.1038/nature05482).
3. Velloso LA, Folli F & Saad MJ. TLR4 at the crossroads of nutrients, gut microbiota, and metabolic inflammation. Endocrine Reviews 2015 36 245-271. (doi:10.1210/er.2014-1100).
4. Eizirik DL, Cardozo AK & Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocrine Reviews 2008 29 42-61. (doi:10.1210/er.2007-0015).
5. Alonso-Magdalena P, Quesada I& Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nature Reviews. Endocrinology 2011 7 346-353. (doi:10.1038/nrendo.2011.56).
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006 444 860-867. (doi:10.1038/nature05485).
7. Velloso LA, Eizirik DL & Cnop M. Type 2 diabetes mellitus - An autoimmune disease? Nature Reviews. Endocrinology 2013 9 750-755. (doi:10.1038/nrendo.2013.131).
8. Mills ES. A fatal case of diabetes mellitus complicated by infection. Canadian Medical Association Journal 1924 14 732-734.
9. Brandaleone H, Standard S & Ralli EP. Prophylactic foot treatment in patients with diabetesmellitus: Analyses of its effect on the prevention of infection of the lower extremities and the operative prognosis in a series of five hundred seventy-six cases. Annals of Surgery 1937 105 120-124. (doi:10.1097/00000658-193701000-00011).
10. Marble A, White HJ & Fernald AT. The nature of the lowered resistance to infection in diabetes mellitus. Journal of Clinical Investigation 1938 17 423-430. (doi:10.1172/JCI100969).
11. Richardson R. Immunity in diabetes. III. Relation of tissue glycogen and blood chemistry to bacterial dissemination, antibody formation and survival after infection in diabetes. Journal of Clinical Investigation 1940 19 239-250. (doi:10.1172/JCI101116).
12. McKittrick LS, McKittrick JB & Risley TS. Transmetatarsal amputation for infection or gangrene in patients with diabetes mellitus. Annals of Surgery 1949 130 826-840. (doi:10.1097/00000658-194910000-00019).
13. Himsworth HP. Insulin deficiency and insulin inefficiency. British Medical Journal 1940 1 719-722. (doi:10.1136/bmj.1.4139.719).
14. Insulin resistance and sensitivity. British Medical Journal 1940 1 734. (doi:10.1136/bmj.1.4139.734).
15. Hotamisligil GS, Shargill NS & Spiegelman BM. Adipose expression of tumor necrosis factor-a: direct role in obesity-linked insulin resistance. Science 1993 259 87-91. (doi:10.1126/science.7678183).
16. Gregor MF & Hotamisligil GS. Inflammatory mechanisms in obesity. Annual Review of Immunology 2011 29 415-445. (doi:10.1146/annurevimmunol- 031210-101322).
17. Richardson SJ, Willcox A, Bone AJ, Foulis AK & Morgan NG. Isletassociated macrophages in type 2 diabetes. Diabetologia 2009 52 1686-1688. (doi:10.1007/s00125-009-1410-z).
18. Donath MY, Boni-Schnetzler M, Ellingsgaard H & Ehses JA. Islet inflammation impairs the pancreatic b-cell in type 2 diabetes. Physiology 2009 24 325-331. (doi:10.1152/physiol.00032.2009).
19. Igoillo-Esteve M, Marselli L, Cunha DA, Ladriere L, Ortis F, Grieco FA, Dotta F, Weir GC, Marchetti P, Eizirik DL et al. Palmitate induces a pro-inflammatory response in human pancreatic islets that mimics CCL2 expression by b cells in type 2 diabetes. Diabetologia 2010 53 1395-1405. (doi:10.1007/s00125-010-1707-y).
20. Stein CJ & Colditz GA. The epidemic of obesity. Journal of Clinical Endocrinology and Metabolism 2004 89 2522-2525. (doi:10.1210/jc. 2004-0288).
21. Moreno LA & Rodriguez G. Dietary risk factors for development of childhood obesity. Current Opinion in Clinical Nutrition and Metabolic Care 2007 10 336-341. (doi:10.1097/MCO.0b013e3280a94f59).
22. Boden G. Obesity, insulin resistance and free fatty acids. Current Opinion in Endocrinology, Diabetes and Obesity 2011 18 139-143. (doi:10.1097/MED.0b013e3283444b09).
23. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV & Ravussin E. A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995 38 1213-1217. (doi:10.1007/BF00422371).
24. deJongh RT, Serne EH, Ijzerman RG, deVries G & Stehouwer CD. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 2004 53 2873-2882. (doi:10.2337/diabetes.53.11.2873).
25. Fagot-Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetiere P & Eschwege E. High free fatty acid concentration: An independent risk factor for hypertension in the Paris Prospective Study. International Journal of Epidemiology 1998 27 808-813. (doi:10.1093/ije/27.5.808).
26. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF & Shulman GI. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C q and alterations in the insulin signaling cascade. Diabetes 1999 48 1270-1274. (doi:10.2337/diabetes.48.6.1270).
27. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010 140 900-917. (doi:10.1016/j.cell. 2010.02.034).
28. Jornayvaz FR & Shulman GI. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metabolism 2012 15 574-584. (doi:10.1016/j.cmet.2012.03.005).
29. Nakamura T, Furuhashi M, Li P, Cao H, Tuncman G, Sonenberg N, Gorgun CZ & Hotamisligil GS. Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 2010 140 338-348. (doi:10.1016/j.cell.2010.01.001).
30. Wolff S, Weissman JS & Dillin A. Differential scales of protein quality control. Cell 2014 157 52-64. (doi:10.1016/j.cell.2014.03.007).
31. Ron D & Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nature Review. Molecular and Cellular Biology 2007 8 519-529. (doi:10.1038/nrm2199).
32. Hollien J. Evolution of the unfolded protein response. Biochimica et Biophysica Acta 2013 1833 2458-2463. (doi:10.1016/j.bbamcr.2013. 01.016).
33. Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. International Journal of Obesity 2008 32 (Suppl 7) S52-S54. (doi:10.1038/ijo.2008.238).
34. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH & Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004 306 457-461. (doi:10.1126/science.1103160).
35. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ & Hotamisligil GS. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006 313 1137-1140. (doi:10.1126/science.1128294).
36. Zhang X, Zhang G, Zhang H, Karin M, Bai H & Cai D. Hypothalamic IKK b/NF-kB and ER stress link overnutrition to energy imbalance and obesity. Cell 2008 135 61-73. (doi:10.1016/j.cell.2008.07.043).
37. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr & Ozcan U. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metabolism 2009 9 35-51. (doi:10.1016/j.cmet.2008.12.004).
38. Milanski M, Degasperi G, Coope A, Morari J, Denis R, Cintra DE, Tsukumo DM, Anhe G, Amaral ME, Takahashi HK et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. Journal of Neuroscience 2009 29 359-370. (doi:10.1523/JNEUROSCI.2760-08.2009).
39. Takeuchi O & Akira S. Pattern recognition receptors and inflammation. Cell 2010 140 805-820. (doi:10.1016/j.cell.2010.01.022).
40. Beutler BA. TLRs and Innate Immunity. Blood 2009 113 1399-1407. (doi:10.1182/blood-2008-07-019307).
41. Kawagoe T, Sato S, Matsushita K, Kato H, Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O & Akira S. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nature Immunology 2008 9 684-691. (doi:10.1038/ni.1606).
42. Lee JY, Sohn KH, Rhee SH & Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. Journal of Biological Chemistry 2001 276 16683-16689. (doi:10.1074/jbc.M011695200).
43. Schaeffler A, Gross P, Buettner R, Bollheimer C, Buechler C, Neumeier M, Kopp A, Schoelmerich J & Falk W. Fatty acid-induced induction of Toll-like receptor-4/nuclear factor-kB pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009 126 233-245. (doi:10.1111/j.1365-2567.2008. 02892.x).
44. Song MJ, Kim KH, Yoon JM & Kim JB. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochemical and Biophysical Research Communications 2006 346 739-745. (doi:10.1016/j.bbrc.2006.05.170).
45. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H & Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 2006 116 3015-3025. (doi:10.1172/JCI28898).
46. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araujo EP, Vassallo J, Curi R, Velloso LA et al. Loss-of-function mutation in Toll-like receptor 4 prevents dietinduced obesity and insulin resistance. Diabetes 2007 56 1986-1998. (doi:10.2337/db06-1595).
47. Milanski M, Arruda AP, Coope A, Ignacio-Souza LM, Nunez CE, Roman EA, Romanatto T, Pascoal LB, Caricilli AM, Torsoni MA et al. Inhibition of hypothalamic inflammation reverses diet-induced insulin resistance in the liver. Diabetes 2012 61 1455-1462. (doi:10.2337/db11-0390).
48. Razolli DS, Moraes JC, Morari J, Moura RF, Vinolo MA & Velloso LA. TLR4 expression in bone marrow-derived cells is both necessary and sufficient to produce the insulin resistance phenotype in diet-induced obesity. Endocrinology 2015 156 103-113. (doi:10.1210/en.2014-1552).
49. Saberi M, Woods NB, de Luca C, Schenk S, Lu JC, Bandyopadhyay G, Verma IM & Olefsky JM. Hematopoietic cell-specific deletion of tolllike receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metabolism 2009 10 419-429. (doi:10.1016/j.cmet.2009.09.006).
50. Weisberg SP, Hunter D, Huber R, Lemieux J, Slaymaker S, Vaddi K, Charo I, Leibel RL & Ferrante AW Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Journal of Clinical Investigation 2006 116 115-124. (doi:10.1172/JCI24335).
51. Schenk S, Saberi M & Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. Journal of Clinical Investigation 2008 118 2992-3002. (doi:10.1172/JCI34260).
52. Erridge C & Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 1944-1949. (doi:10.1161/ATVBAHA.109.194050).
53. Brandl K, Gluck T, Hartmann P, Salzberger B & Falk W. A designed TLR4/MD-2 complex to capture LPS. Journal of Endotoxin Research 2005 11 197-206. (doi:10.1177/09680519050110040301).
54. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS & Bhattacharya S. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nature Medicine 2012 18 1279-1285. (doi:10.1038/nm.2851).
55. Chatterjee P, Seal S, Mukherjee S, Kundu R, Mukherjee S, Ray S, Mukhopadhyay S, Majumdar SS & Bhattacharya S. Adipocyte fetuin-A contributes to macrophage migration into adipose tissue and polarization of macrophages. Journal of Biological Chemistry 2013 288 28324-28330. (doi:10.1074/jbc.C113.495473).
56. Stefan N & Haring HU. Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nature Medicine 2013 19 394-395. (doi:10.1038/nm.3116).
57. Sun Q, Cornelis MC, Manson JE & Hu FB. Plasma levels of fetuin-A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 2013 62 49-55. (doi:10.2337/db12-0372).
58. Jensen MK, Bartz TM, Mukamal KJ, Djousse L, Kizer JR, Tracy RP, Zieman SJ, Rimm EB, Siscovick DS, Shlipak M et al. Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: The cardiovascular health study. Diabetes Care 2013 36 1222-1228. (doi:10.2337/dc12-1591).
59. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007 56 1761-1772. (doi:10.2337/db06-1491).
60. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM & Dandona P. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a highfat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009 32 2281-2287. (doi:10.2337/dc09-0979).
61. Caricilli AM, Picardi PK, de Abreu LL, Ueno M, Prada PO, Ropelle ER, Hirabara SM, Castoldi A, Vieira P, Camara NO et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biology 2011 9 e1001212. (doi:10.1371/journal.pbio.1001212).
62. Lassenius MI, Pietilainen KH, Kaartinen K, Pussinen PJ, Syrjanen J, Forsblom C, Porsti I, Rissanen A, Kaprio J, Mustonen J et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011 34 1809-1815. (doi:10.2337/dc10-2197).
63. Cani PD, Osto M, Geurts L & Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012 3 279-288. (doi:10.4161/gmic.19625).
64. Karlsson F, Tremaroli V, Nielsen J & Backhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 2013 62 3341-3349. (doi:10.2337/db13-0844).
65. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine 2013 19 576-585. (doi:10.1038/nm.3145).
66. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011 334 105-108. (doi:10.1126/science.1208344).
67. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, SargentM, Gill SR, Nelson KE & Relman DA. Diversity of the human intestinal microbial flora. Science 2005 308 1635-1638. (doi:10.1126/science. 1110591).
68. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER & Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006 444 1027-1031. (doi:10.1038/nature05414).
69. Murphy EF, Cotter PD, Healy S, Marques TM, O'Sullivan O, Fouhy F, Clarke SF, O'Toole PW, Quigley EM, Stanton C et al. Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 2010 59 1635-1642. (doi:10.1136/gut.2010.215665).
70. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM & Burcelin R. Changes in gut microbiota control metabolic endotoxemia- induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008 57 1470-1481. (doi:10.2337/db07-1403).
71. Itani SI, Ruderman NB, Schmieder F & Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-a. Diabetes 2002 51 2005-2011. (doi:10.2337/diabetes.51.7.2005).
72. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ & Shulman GI. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. Journal of Biological Chemistry 2004 279 32345-32353. (doi:10.1074/jbc.M313478200).
73. Chalfant CE, Ciaraldi TP, Watson JE, Nikoulina S, Henry RR & Cooper DR. Protein kinase Cq expression is increased upon differentiation of human skeletal muscle cells: dysregulation in type 2 diabetic patients and a possible role for protein kinase Cq in insulin-stimulated glycogen synthase activity. Endocrinology 2000 141 2773-2778. (doi:10.1210/endo.141.8.7591).
74. Farese RV, Sajan MP & Standaert ML. Atypical protein kinase C in insulin action and insulin resistance. Biochemical Society Transactions 2005 33 350-353. (doi:10.1042/BST0330350).
75. Levin DH, Petryshyn R & London IM. Characterization of doublestranded- RNA-activated kinase that phosphorylates a subunit of eukaryotic initiation factor 2 (eIF-2 a) in reticulocyte lysates. PNAS 1980 77 832-836. (doi:10.1073/pnas.77.2.832).
76. Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C & Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiology and Molecular Biology Reviews 2006 70 1032-1060. (doi:10.1128/MMBR.00027-06).
77. Carvalho BM, Oliveira AG, Ueno M, Araujo TG, Guadagnini D, Carvalho-Filho MA, Geloneze B, Lima MM, Pareja JC, Carvalheira JB et al. Modulation of double-stranded RNA-activated protein kinase in insulin sensitive tissues of obese humans. Obesity 2013 21 2452-2457. (doi:10.1002/oby.20410) 78 Nakamura T, Arduini A, Baccaro B, Furu.
78. hashi M & Hotamisligil GS. Small-molecule inhibitors of PKR improve glucose homeostasis in obese diabetic mice. Diabetes 2014 63 526-534. (doi:10.2337/db13-1019).
79. Velloso LA. Turning off a viral/lipid sensor improves type 2 diabetes. Diabetes 2014 63 393-395. (doi:10.2337/db13-1704).
80. Sabio G & Davis RJ. cJun NH2-terminal kinase 1 (JNK1): roles in metabolic regulation of insulin resistance. Trends in Biochemical Science 2010 35 490-496. (doi:10.1016/j.tibs.2010.04.004).
81. Tarantino G & Caputi A. JNKs, insulin resistance and inflammation: A possible link between NAFLD and coronary artery disease. World Journal of Gastroenterology 2011 17 3785-3794. (doi:10.3748/wjg.v17.i33.3785).
82. Manieri E & Sabio G. Stress kinases in the modulation of metabolism and energy balance. Journal of Molecular Endocrinology 2015 55 R11-R22. (doi:10.1530/JME-15-0146).
83. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE & Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996 274 1377-1379. (doi:10.1126/science. 274.5291.1377).
84. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, Karin M & Hotamisligil GS. A central role for JNK in obesity and insulin resistance. Nature 2002 420 333-336. (doi:10.1038/nature01137).
85. Coope A, Milanski M, Arruda AP, Ignacio-Souza LM, Saad MJ, Anhe GF & Velloso LA. Chaperone insufficiency links TLR4 protein signaling to endoplasmic reticulum stress. Journal of Biological Chemistry 2012 287 15580-15589. (doi:10.1074/jbc.M111.315218).
86. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP & Ron D. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science 2000 287 664-666. (doi:10.1126/science.287.5453.664).
87. Belgardt BF, Mauer J, Wunderlich FT, Ernst MB, Pal M, Spohn G, Bronneke HS, Brodesser S, Hampel B, Schauss AC et al. Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. PNAS 2010 107 6028-6033. (doi:10.1073/pnas.1001796107).
88. Tsaousidou E, Paeger L, Belgardt BF, Pal M, Wunderlich CM, Bronneke H, Collienne U, Hampel B, Wunderlich FT, Schmidt- Supprian M et al. Distinct roles for JNK and IKK activation in agoutirelated peptide neurons in the development of obesity and insulin resistance. Cell Reports 2014 9 1495-1506. (doi:10.1016/j.celrep.2014.10.045).
89. Baker RG, Hayden MS & Ghosh S. NF-kB, inflammation, and metabolic disease. Cell Metabolism 2011 13 11-22. (doi:10.1016/j.cmet.2010.12.008).
90. Israel A. The IKK, complex, a central regulator of NF-kB activation. Cold Spring Harbor Perspectives in Biology 2010 2 a000158. (doi:10.1101/cshperspect.a000158).
91. HaydenMS & Ghosh S. Shared principles in NF-kB signaling. Cell 2008 132 344-362. (doi:10.1016/j.cell.2008.01.020).
92. Hotamisligil GS & Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nature Reviews Immunology 2008 8 923-934. (doi:10.1038/nri2449).
93. Foster SL, Hargreaves DC & Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007 447 972-978. (doi:10.1038/nature05836).
94. Paneni F, Costantino S, Volpe M, Luscher TF & Cosentino F. Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. Atherosclerosis 2013 230 191-197. (doi:10.1016/j.atherosclerosis.2013.07.003).
95. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P et al. Prevention of fat-induced insulin resistance by salicylate. Journal of Clinical Investigation 2001 108 437-446. (doi:10.1172/JCI11559).
96. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J & Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-kB. Nature Medicine 2005 11 183-190. (doi:10.1038/nm1166).
97. Le KA, Mahurkar S, Alderete TL, Hasson RE, Adam TC, Kim JS, Beale E, Xie C, Greenberg AS, Allayee H et al. Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-kB stress pathway. Diabetes 2011 60 2802-2809. (doi:10.2337/db10-1263).
98. Kim SH, Liu A, Ariel D, Abbasi F, Lamendola C, Grove K, Tomasso V, Ochoa H & Reaven G. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: A randomized, placebo-controlled study. Diabetes Care 2014 37 1944-1950. (doi:10.2337/dc13-2977).
99. Schmelzle T & Hall MN. TOR, a central controller of cell growth. Cell 2000 103 253-262. (doi:10.1016/S0092-8674(00)00117-3).
100. Kim SG, Buel GR & Blenis J. Nutrient regulation of the mTOR complex 1 signaling pathway. Molecules and Cells 2013 35 463-473. (doi:10.1007/s10059-013-0138-2).
101. Ma XM & Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nature Review. Molecular and Cellular Biology 2009 10 307-318. (doi:10.1038/nrm2672).
102. Laplante M & Sabatini DM. mTOR signaling in growth control and disease. Cell 2012 149 274-293. (doi:10.1016/j.cell.2012.03.017).
103. Zoncu R, Efeyan A & Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Review. Molecular and Cellular Biology 2011 12 21-35. (doi:10.1038/nrm3025).
104. Kim JH, Kim JE, Liu HY, CaoW& Chen J. Regulation of interleukin-6- induced hepatic insulin resistance bymammalian target of rapamycin through the STAT3-SOCS3 pathway. Journal of Biological Chemistry 2008 283 708-715. (doi:10.1074/jbc.M708568200).
105. Jiang H, Westerterp M, Wang C, Zhu Y & Ai D. Macrophage mTORC1 disruption reduces inflammation and insulin resistance in obese mice. Diabetologia 2014 57 2393-2404. (doi:10.1007/s00125-014-3350-5).
106. Greene MW, Sakaue H, Wang L, Alessi DR & Roth RA. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. Journal of Biological Chemistry 2003 278 8199-8211. (doi:10.1074/jbc.M209153200).
107. Manning BD. Balancing Akt with S6K: implications for bothmetabolic diseases and tumorigenesis. Journal of Cell Biology 2004 167 399-403. (doi:10.1083/jcb.200408161).
108. Cawthorn WP & Sethi JK. TNF-a and adipocyte biology. FASEB Letters 2008 582 117-131. (doi:10.1016/j.febslet.2007.11.051).
109. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL & Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation 2003 112 1796-1808. (doi:10.1172/JCI200319246).
110. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H & Shimoda T. Transmembrane TNF-a: structure, function and interaction with anti- TNF agents. Rheumatology 2010 49 1215-1228. (doi:10.1093/rheumatology/keq031).
111. Romanatto T, Roman EA, Arruda AP, Denis RG, Solon C, Milanski M, Moraes JC, Bonfleur ML, Degasperi GR, Picardi PK et al. Deletion of tumor necrosis factor-a receptor 1 (TNFR1) protects against dietinduced obesity by means of increased thermogenesis. Journal of Biological Chemistry 2009 284 36213-36222. (doi:10.1074/jbc.M109. 030874).
112. Uysal KT, Wiesbrock SM, Marino MW & Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-a function. Nature 1997 389 610-614. (doi:10.1038/39335).
113. Ouchi N, Parker JL, Lugus JJ & Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology 2011 11 85-97. (doi:10.1038/nri2921).
114. Hotamisligil GS, Budavari A, Murray D & Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-a. Journal of Clinical Investigation 1994 94 1543-1549. (doi:10.1172/JCI117495).
115. Yazdani-Biuki B, Stelzl H, Brezinschek HP, Hermann J, Mueller T, Krippl P, Graninger W & Wascher TC. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-a antibody infliximab. European Journal of Clinical Investigation 2004 34 641-642. (doi:10.1111/j.1365-2362.2004.01390.x).
116. Stanley TL, Zanni MV, Johnsen S, Rasheed S, Makimura H, Lee H, Khor VK, Ahima RS & Grinspoon SK. TNF-a antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 E146-E150. (doi:10.1210/jc.2010-1170).
117. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annual Review of Immunology 2009 27 519-550. (doi:10.1146/annurev.immunol.021908.132612).
118. Strowig T, Henao-Mejia J, Elinav E & Flavell R. Inflammasomes in healthanddisease. Nature 2012 481 278-286. (doi:10.1038/nature10759).
119. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA & Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986 232 1545-1547. (doi:10.1126/science.3086977).
120. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA & Donath MY. Glucose-induced b cell production of IL-1b contributes to glucotoxicity in human pancreatic islets. Journal of Clinical Investigation 2002 110 851-860. (doi:10.1172/JCI200215318).
121. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A & Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: A possible link to the resistance to leptin? Journal of Clinical Endocrinology and Metabolism 2002 87 1184-1188. (doi:10.1210/jcem.87.3.8351).
122. Dinarello CA, DonathMY & Mandrup-Poulsen T. Role of IL-1b in type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity 2010 17 314-321. (doi:10.1097/MED.0b013e32833bf6dc).
123. McGillicuddy FC, Harford KA, Reynolds CM, Oliver E, Claessens M, Mills KH & Roche HM. Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes 2011 60 1688-1698. (doi:10.2337/db10-1278).
124. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM & Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nature Medicine 2011 17 179-188. (doi:10.1038/nm.2279).
125. Ballak DB, Stienstra R, Tack CJ, Dinarello CA & vanDiepen JA. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine 2015 75 280-290. (doi:10.1016/j.cyto.2015.05.005).
126. Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, Berg JK & Landschulz WH. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1b antibody, in patients with type 2 diabetes. Diabetes Care 2013 36 2239-2246. (doi:10.2337/dc12-1835).
127. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J & Thuren T. Effects of interleukin-1b inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: A phase IIb randomized, placebo-controlled trial. Circulation 2012 126 2739-2748. (doi:10.1161/CIRCULATIONAHA.112.122556).
128. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986 324 73-76. (doi:10.1038/324073a0).
129. Calabrese LH & Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nature Reviews. Rheumatology 2014 10 720-727. (doi:10.1038/nrrheum.2014.127).
130. Tanaka T & Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunology Research 2014 2 288-294. (doi:10.1158/2326-6066.CIR-14-0022).
131. Barnes TC, AndersonME & Moots RJ. The many faces of interleukin-6: The role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. International Journal of Rheumatology 2011 2011 721608. (doi:10.1155/2011/721608).
132. Scheller J, Chalaris A, Schmidt-Arras D & Rose-John S. The pro- And anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta 2011 1813 878-888. (doi:10.1016/j.bbamcr.2011.01.034).
133. Klover PJ, Clementi AH & Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005 146 3417-3427. (doi:10.1210/en.2004-1468).
134. Pradhan AD, Manson JE, Rifai N, Buring JE & Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of American Medical Association 2001 286 327-334. (doi:10.1001/jama.286.3.327).
135. Fried SK, Bunkin DA & Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. Journal of Clinical Endocrinology and Metabolism 1998 83 847-850. (doi:10.1210/jcem.83.3.4660).
136. Rotter V, Nagaev I & Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-a, overexpressed in human fat cells from insulin-resistant subjects. Journal of Biological Chemistry 2003 278 45777-45784. (doi:10.1074/jbc.M301977200).
137. Piya MK, McTernan PG & Kumar S. Adipokine inflammation and insulin resistance: The role of glucose, lipids and endotoxin. Journal of Endocrinology 2013 216 T1-T15. (doi:10.1530/JOE-12-0498).
138. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007 56 2356-2370. (doi:10.2337/db06-1650).
139. Lima MM, Pareja JC, Alegre SM, Geloneze SR, Kahn SE, Astiarraga BD, Chaim EA, Baracat J & Geloneze B. Visceral fat resection in humans: effect on insulin sensitivity, b-cell function, adipokines, and inflammatory markers. Obesity 2013 21 E182-E189. (doi:10.1002/oby.20030).
140. Calegari VC, Torsoni AS, Vanzela EC, Araujo EP, Morari J, Zoppi CC, Sbragia L, Boschero AC & Velloso LA. Inflammation of the hypothalamus leads to defective pancreatic islet function. Journal of Biological Chemistry 2011 286 12870-12880. (doi:10.1074/jbc.M110. 173021).
141. Nicol LE, Grant WF, Comstock SM, Nguyen ML, Smith MS, Grove KL & Marks DL. Pancreatic inflammation and increased islet macrophages in insulin-resistant juvenile primates. Journal of Endocrinology 2013 217 207-213. (doi:10.1530/JOE-12-0424).
142. Schroder K & Tschopp J. The inflammasomes. Cell 2010 140 821-832. (doi:10.1016/j.cell.2010.01.040).
143. Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, Becker C, Franchi L, Yoshihara E, Chen Z et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nature Immunology 2010 11 897-904. (doi:10.1038/ni.1935).
144. Westwell-Roper C, Dai DL, Soukhatcheva G, Potter KJ, van Rooijen N, Ehses JA & Verchere CB. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. Journal of Immunology 2011 187 2755-2765. (doi:10.4049/jimmunol.1002854).
145. Sauter NS, Schulthess FT, Galasso R, Castellani LW & Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 2008 149 2208-2218. (doi:10.1210/en.2007-1059).
146. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, Dayer JM, Reinecke M, Halban PA & Donath MY. Leptin modulates b cell expression of IL-1 receptor antagonist and release of IL-1b in human islets. PNAS 2004 101 8138-8143. (doi:10.1073/pnas.0305683101).
147. Cnop M, Foufelle F & Velloso LA. Endoplasmic reticulum stress, obesity and diabetes. Trends in Molecular Medicine 2012 18 59-68. (doi:10.1016/j.molmed.2011.07.010).
148. Colombo C, Porzio O, Liu M, Massa O, Vasta M, Salardi S, Beccaria L, Monciotti C, Toni S, Pedersen O et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. Journal of Clinical Investigation 2008 118 2148-2156. (doi:10.1172/JCI33777).
149. Stoy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, Hayes MG, Cox NJ, Lipkind GM et al. Insulin gene mutations as a cause of permanent neonatal diabetes. PNAS 2007 104 15040-15044. (doi:10.1073/pnas.0707291104).
150. Seo HY, Kim YD, Lee KM, Min AK, KimMK, Kim HS, Won KC, Park JY, Lee KU, Choi HS et al. Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases insulin gene expression via up-regulation of orphan nuclear receptor small heterodimer partner. Endocrinology 2008 149 3832-3841. (doi:10.1210/en.2008-0015).
151. Lipson KL, Ghosh R & Urano F. The role of IRE1a in the degradation of insulin mRNA in pancreatic b-cells. PLoS ONE 2008 3 e1648. (doi:10.1371/journal.pone.0001648).
152. Cunha DA, Hekerman P, Ladriere L, Bazarra-Castro A, Ortis F, Wakeham MC, Moore F, Rasschaert J, Cardozo AK, Bellomo E et al. Initiation and execution of lipotoxic ER stress in pancreatic b-cells. Journal of Cell Science 2008 121 2308-2318. (doi:10.1242/jcs.026062).
153. Eizirik DL, Miani M & Cardozo AK. Signalling danger: endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. Diabetologia 2013 56 234-241. (doi:10.1007/s00125-012-2762-3).
154. Lenzen S, Drinkgern J & Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radical Biology & Medicine 1996 20 463-466. (doi:10.1016/0891-5849(96)02051-5).
155. Zhou R, Tardivel A, Thorens B, Choi I & Tschopp J. Thioredoxininteracting protein links oxidative stress to inflammasome activation. Nature Immunology 2010 11 136-140. (doi:10.1038/ni.1831).
156. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ & Ting JP. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunology 2011 12 408-415. (doi:10.1038/ni.2022).
157. Weaver JR, Holman TR, Imai Y, Jadhav A, Kenyon V, Maloney DJ, Nadler JL, Rai G, Simeonov A & Taylor-Fishwick DA. Integration of pro-inflammatory cytokines, 12-lipoxygenase and NOX-1 in pancreatic islet b cell dysfunction. Molecular and Cellular Endocrinology 2012 358 88-95. (doi:10.1016/j.mce.2012.03.004).
158. Tersey SA, Maier B, Nishiki Y, Maganti AV, Nadler JL & Mirmira RG. 12-lipoxygenase promotes obesity-induced oxidative stress in pancreatic islets. Molecular and Cellular Biology 2014 34 3735-3745. (doi:10.1128/MCB.00157-14).
159. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T & Donath MY. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine 2007 356 1517-1526. (doi:10.1056/NEJMoa065213).
160. Gilgore SG & Rupp JJ. The long-term response of diabetes mellitus to salicylate therapy: report of a case. Journal of American Medical Association 1962 180 65-66. (doi:10.1001/jama.1962. 03050140067017c).
161. Goldfine AB, Conlin PR, Halperin F, Koska J, Permana P, Schwenke D, Shoelson SE & Reaven PD. A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance. Diabetologia 2013 56 714-723. (doi:10.1007/s00125-012-2819-3).
162. Fleischman A, Shoelson SE, Bernier R & Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008 31 289-294. (doi:10.2337/dc07-1338).
163. Reitman ML & Schadt EE. Pharmacogenetics ofmetformin response: A step in the path toward personalized medicine. Journal of Clinical Investigation 2007 117 1226-1229. (doi:10.1172/JCI32133).